Prostate cancer has the widest racial disparities of any cancer, and these disparities appear
at every stage of the cancer continuum. This review focuses on the disparities in prostate …

Despite advances in the screening and treatment of prostate cancer, the therapy options
available, particularly for later stages of the disease, remain limited, and the treatment …

Background Retrospective analyses of randomized trials suggest that Black men with
metastatic castration‐resistant prostate cancer (mCRPC) have longer survival than White …

Prostate cancer remains the leading diagnosed cancer and the second leading cause of
death among American men. Despite improvements in screening modalities, diagnostics …

PURPOSE Prostate cancer represents the most common cancer diagnosis in Black men and
is the second leading cause of cancer death in this population. Multilevel disparities have …

Background Prostate cancer in black men is associated with poorer outcomes than their
white counterparts. However, most studies reporting this disparity were conducted in …

Purpose: Several recent studies on metastatic castration resistant prostate cancer
demonstrated improved overall survival in black vs white men. 223Radium is Food and Drug …

Despite notable screening, diagnostic, and therapeutic advances, disparities in prostate
cancer incidence and outcomes remain prevalent. Although commonly discussed in the …

Repetitive, low-dose (metronomic; METRO) drug administration of some anticancer agents
can overcome drug resistance and increase drug efficacy in many cancers, but the …

Background Docetaxel (DOC) and abiraterone (ABI) in the upfront setting have separately
improved clinical outcomes for metastatic hormone-sensitive prostate cancer (mHSPC), but …